Clinical trial / 2002
In patients with type 2 diabetes and dyslipidemia, policosanol reduced LDL-C by 29.9% and increased HDL-C more effectively than lovastatin.
In a pilot, double-blind study, 36 patients with dyslipidemia and type 2 diabetes on a cholesterol-lowering diet were randomized to receive policosanol (10 mg/day) or lovastatin (20 mg/day) for 8 weeks. Policosanol significantly lowered LDL-C by 29.9%, total cholesterol by 21.1%, triglycerides by 13.6%, and increased HDL-C by 12.5%, outperforming lovastatin in raising HDL-C and reducing lipid ratios (p < 0.05). Policosanol also improved lag time of LDL peroxidation by 20.9% and plasma antioxidant activity by 24.2%. Both treatments reduced lipid peroxidation markers and were well tolerated, though the authors note further studies with larger sample sizes are required.
- Study type
- Pilot, randomized, double-blind study
- Who was studied
- 36 patients with dyslipidemia and type 2 diabetes mellitus
- What was measured
- Lipid profile and lipid peroxidation markers
THE PAPER
Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Castaño G, Menéndez R, Más R, Amor A, Fernández JL, González RL, Lezcay M, Alvarez E. Int J Clin Pharmacol Res, 2002.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.